Atossa Therapeutics Announces Sponsorship of Are You Dense MusicFest 2023
23 June 2023 - 6:15AM
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage
biopharmaceutical company developing innovative proprietary
medicines to address significant unmet needs in oncology with a
focus on breast cancer, today announces their role as a corporate
sponsor of the Are You Dense MusicFest 2023. The event will take
place on Saturday, June 24 at the Seven Angels Theater in
Waterbury, Connecticut. Tickets are available and can be purchased
through the Seven Angels Theater website.
The Are You Dense MusicFest is an annual event hosted by Are You
Dense, Inc., an organization dedicated to educating the public
about the risks and screening challenges of dense breast tissue and
its impact on missed, delayed and advanced stage breast cancer. The
organization was founded by Dr. Nancy Cappello who, just six weeks
after her 11th-consecutive normal mammogram, was diagnosed with
late-stage breast cancer. As part of her diagnosis, Dr. Cappello
learned that she had dense breast tissue, which both decreases the
effectiveness of mammograms and significantly increases the risk of
developing breast cancer. Approximately half of women over the age
of 40 in the U.S. have dense breast tissue.
Are You Dense, Inc. exists to further the following goals:
- Educate the public about breast health including the impact of
dense breast tissue.
- Improve the condition of those diagnosed with breast
cancer.
- Advocate changes to public policy about the prevention and
treatment of breast cancer including breast cancer screening
guidelines.
- Support new and existing research about the prevention and
treatment of breast cancer and the causal and screening risks of
dense breast tissue and its impact on advanced disease.
“We are grateful for Atossa’s support of our MusicFest event and
our mission to educate the public about the risks and screening
challenges of dense breast tissue,” said Joseph J. Cappello, Are
You Dense, Inc.’s Executive Director. “While the gold standard for
breast cancer screening is mammography, in women with dense breast
tissue, up to one third of breast cancers can be missed with this
modality.”
One of the many important contributions made by the organization
was launching the move for legislative action around breast
density. Thanks to Dr. Cappello’s tireless efforts, the US Food and
Drug Administration updated the Mammography Quality Standards Act
to require mammogram providers to inform patients about the density
of their breasts and include specific language in the mammogram
reports to explain how breast density can influence the accuracy of
a mammogram. Additionally, the FDA is requiring mammogram
facilities recommend that patients with dense breasts talk to their
health care provider about breast density, risks for breast cancer
and their individual situation.
“Atossa is proud to support the Are You Dense MusicFest and the
great work this organization does to educate and advocate on behalf
of women with dense breast tissue,” said Dr. Steven Quay, Atossa’s
President and Chief Executive Officer. “Breast density is an
emerging public health issue and the millions of women affected
need treatment options to proactively reduce the density of their
breasts, which will not only improve mammography, but will also
reduce the likelihood that they will develop breast cancer.”
About Atossa TherapeuticsAtossa Therapeutics,
Inc. is a clinical-stage biopharmaceutical company developing
innovative medicines in areas of significant unmet medical need in
oncology with a focus on breast cancer. For more information,
please visit www.atossatherapeutics.com
CONTACT:Eric Van ZantenVP, Investor and Public
Relations610-529-6219eric.vanzanten@atossainc.com
FORWARD LOOKING STATEMENTSForward-looking
statements in this press release, which Atossa undertakes no
obligation to update, are subject to risks and uncertainties that
may cause actual results to differ materially from the anticipated
or estimated future results, including the risks and uncertainties
associated with any variation between interim and final clinical
results, actions and inactions by the FDA, the outcome or timing of
regulatory approvals needed by Atossa including those needed to
commence studies of (Z)-endoxifen, lower than anticipated rate of
patient enrollment, estimated market size of drugs under
development, the safety and efficacy of Atossa’s products,
performance of clinical research organizations and investigators,
obstacles resulting from proprietary rights held by others such as
patent rights, whether reduction in breast density or in Ki-67 or
any other result from a neoadjuvant study is an approvable endpoint
for (Z)-endoxifen, whether Atossa can complete acquisitions, and
other risks detailed from time to time in Atossa’s filings with the
Securities and Exchange Commission, including without limitation
its periodic reports on Form 10-K and 10-Q, each as amended and
supplemented from time to time.
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Jul 2023 to Jul 2024